Literature DB >> 12845675

A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter is associated with conventional renal cell carcinoma.

Hiroshi Hirata1, Katsusuke Naito, Satoru Yoshihiro, Hideyasu Matsuyama, Yutaka Suehiro, Yuji Hinoda.   

Abstract

Matrix metalloproteinase (MMP)-1 is associated with tumor cell invasion and metastasis, and its promoter polymorphism has been shown to influence the transcriptional level. Our study explored the association between this polymorphism and renal cell carcinoma in a Japanese population. DNA was extracted from peripheral blood and normal tissue of 119 patients with conventional renal cell carcinoma (RCC) and from 210 age- and sex-matched healthy volunteers. Genotyping was carried out using direct sequencing. In the MMP-1 gene promoter polymorphism, it was demonstrated that the frequency of the 2G/2G genotype, which is associated with higher enzyme activity, was significantly higher in patients with RCC than in controls (p = 0.0015; OR = 2.082; 95% CI 1.317-3.293). When stratified for gender, only men showed a significant association of the polymorphism with RCC (p = 0.0028; OR = 2.307; 95% CI 1.333-3.990). However, no significant association was observed between the 2G/2G genotype and clinicopathologic parameters including age, gender, tumor grade and pathologic stage. Our present data suggest that the MMP-1 promoter polymorphism may be linked to susceptibility for conventional RCC. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12845675     DOI: 10.1002/ijc.11229

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  16 in total

1.  The polymorphism MMP1 -1607 (1G>2G) is associated with a significantly increased risk of cancers from a meta-analysis.

Authors:  Lili Lu; Yujiao Sun; Yiqun Li; Ping Wan
Journal:  Tumour Biol       Date:  2014-11-13

2.  No association of the matrix metalloproteinase 1 promoter polymorphism with susceptibility to esophageal squamous cell carcinoma and gastric cardiac adenocarcinoma in northern China.

Authors:  Xia Jin; Gang Kuang; Li-Zhen Wei; Yan Li; Rui Wang; Wei Guo; Na Wang; Shu-Mei Fang; Deng-Gui Wen; Zhi-Feng Chen; Jian-Hui Zhang
Journal:  World J Gastroenterol       Date:  2005-04-28       Impact factor: 5.742

3.  Fisetin suppresses ADAM9 expression and inhibits invasion of glioma cancer cells through increased phosphorylation of ERK1/2.

Authors:  Chien-Min Chen; Yi-Hsien Hsieh; Jin-Ming Hwang; Hsun-Jin Jan; Shu-Ching Hsieh; Shin-Huey Lin; Chung-Yu Lai
Journal:  Tumour Biol       Date:  2014-12-20

4.  Association of matrix metalloproteinase-1 gene polymorphism with glioblastoma multiforme in a northern Indian population.

Authors:  Nitin Malik; Raj Kumar; Kashi N Prasad; Priyanka Kawal; Arun Srivastava; Ashok K Mahapatra
Journal:  J Neurooncol       Date:  2010-08-14       Impact factor: 4.130

5.  Association between matrix metalloproteinase 1 -1607 1G>2G polymorphism and cancer risk: a meta-analysis including 19706 subjects.

Authors:  Guoda Han; Zhijiang Wei; Zhiliang Lu; Haibin Cui; Xiyong Bai; Huai'e Ge; Wei Zhang
Journal:  Int J Clin Exp Med       Date:  2014-09-15

6.  Polymorphisms in the matrix metalloproteinase-1, 3, and 9 promoters and susceptibility to adult astrocytoma in northern China.

Authors:  Zhongqiang Lu; Yanyan Cao; Yimin Wang; Qingjun Zhang; Xianghong Zhang; Shuheng Wang; Yuehong Li; Huiling Xie; Baohua Jiao; Jianhui Zhang
Journal:  J Neurooncol       Date:  2007-05-15       Impact factor: 4.130

7.  Licochalcone A inhibits the migration and invasion of human lung cancer cells via inactivation of the Akt signaling pathway with downregulation of MMP-1/-3 expression.

Authors:  Hung-Che Huang; Lo-Lin Tsai; Jen-Pi Tsai; Shu-Ching Hsieh; Shun-Fa Yang; Jung-Tsung Hsueh; Yi-Hsien Hsieh
Journal:  Tumour Biol       Date:  2014-08-23

8.  Analysis of germline variants in CDH1, IGFBP3, MMP1, MMP3, STK15 and VEGF in familial and sporadic renal cell carcinoma.

Authors:  Christopher Ricketts; Maurice P Zeegers; Jan Lubinski; Eamonn R Maher
Journal:  PLoS One       Date:  2009-06-24       Impact factor: 3.240

9.  The expression and clinical significance of matrix metalloproteinase 7 and tissue inhibitor of matrix metalloproteinases 2 in clear cell renal cell carcinoma.

Authors:  Hongsheng Lu; Zhaohui Yang; Hui Zhang; Meifu Gan; Tao Zhou; Siling Wang
Journal:  Exp Ther Med       Date:  2012-12-17       Impact factor: 2.447

10.  Polymorphism +17 C/G in matrix metalloprotease MMP8 decreases lung cancer risk.

Authors:  Patricia González-Arriaga; M Felicitas López-Cima; Ana Fernández-Somoano; Teresa Pascual; Manuel G Marrón; Xose S Puente; Adonina Tardón
Journal:  BMC Cancer       Date:  2008-12-19       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.